Acute Infusion Expansion Confirms Mix-Led Growth, but Volume Decline and Cost Pressures Persist

What happened

BrightSpring's acute infusion business is reportedly growing volumes at over 20% year-over-year and expanding into 12-15 new states, targeting a $20 billion market. This aligns with management's commentary in Q1'26 that specialty and infusion scripts grew ~30% YoY, a key driver of mix-led revenue growth. However, the news does not address the core fragility flagged in our master report: total Pharmacy Solutions prescriptions dispensed declined ~1% YoY, and Home & Community Pharmacy revenue fell 9.2% due to IRA pressures. Moreover, Pharmacy Solutions SG&A rose 35.7% YoY, indicating that scaling into new states and infusion services is not yet translating into operating leverage. While the acute infusion momentum is a positive signal, it is already partially reflected in the stock's valuation at 26x EV/EBITDA, and we see no change to our WAIT stance.

Implication

Investors should treat the Zacks article as a reinforcing data point for the specialty/infusion mix story, but not as a catalyst to upgrade. The 20%+ volume growth in acute infusion is consistent with management's ~30% specialty/infusion script growth, yet it has not prevented total scripts from declining. The push into 12-15 new states will likely add SG&A and capital expenditures before generating returns, worsening the near-term cost problem. The persistent sponsor selling and potential post-lock-up secondary remain key risks that the article ignores. We maintain our WAIT rating and would look to accumulate only on pullbacks toward $55 or after evidence that total scripts stabilize and SG&A growth moderates.

Thesis delta

The news article adds detail on acute infusion expansion but does not alter our core thesis. We continue to view BTSG as a mix-led growth story with deteriorating volume and rising costs, warranting a WAIT. The positive infusion data point is already incorporated in our base-case scenario.